Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy

Oral Oncol. 2013 Apr;49(4):322-5. doi: 10.1016/j.oraloncology.2012.10.005. Epub 2012 Oct 31.

Abstract

Objectives: The purpose of this study was to evaluate the prognostic significance of the expression of metalloproteinases (MMPs)-2 and -9 at a transcriptional level in patients with head and neck squamous cell carcinoma (HNSCC).

Patients and methods: Real-time polymerase chain reaction was used to determine mRNA expression levels of MMP-2 and MMP-9 in 105 consecutive patients with HNSCC treated with radiotherapy or chemoradiotherapy. Continuous values of mRNA expression levels were analyzed using a classification and regression tree (CART) method.

Results: Patients were grouped into two categories according to the results from CART analysis; high (n=71) and low (n=34) expression levels of MMP-9. MMP-2 expression was not included in the model. The 5-year adjusted survival rate was 92.9% for patients with low MMP-9 expression level and 61.0% for patients with a high expression level (P=0.006). Overexpression of MMP-9 was associated with a decrease in local control of the disease. In a multivariate analysis, MMP-9 expression was the only variable that was associated with adjusted survival. Considering patients with a low MMP-9 expression level as the reference group, patients with a high MMP-9 expression level had a 6.1 times higher risk of death from HNSCC (CI 95%: 1.4-26.4).

Conclusion: We found a significant relationship between the transcription of MMP-9 and adjusted survival in HNSCC patients treated with radiotherapy or chemoradiotherapy. These results suggest that MMP-9 transcription may serve as a marker of treatment response to radiotherapy or chemo-radiotherapy in patients with HNSCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / enzymology*
  • Carcinoma, Squamous Cell / radiotherapy
  • Combined Modality Therapy
  • Female
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / enzymology*
  • Head and Neck Neoplasms / radiotherapy
  • Humans
  • Male
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism*
  • Middle Aged
  • Prognosis
  • RNA, Messenger / genetics
  • Real-Time Polymerase Chain Reaction

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • RNA, Messenger
  • Matrix Metalloproteinase 9